The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
We investigated the in vivo function of the B7 family member B7-H3 (also known as B7RP-2) by gene targeting. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3-deficient mice developed more severe airway inflammation than did wild-type mice in conditions in which T helper cells differentiated toward type 1 (T(H)1) rather than type 2 (T(H)2). B7-H3 expression was consistently enhanced by interferon-gamma but suppressed by interleukin 4 in dendritic cells. B7-H3-deficient mice developed experimental autoimmune encephalomyelitis several days earlier than their wild-type littermates, and accumulated higher concentrations of autoantibodies to DNA. Thus, B7-H3 is a negative regulator that preferentially affects T(H)1 responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, CD276 (B7-H3), known to augment Tregs and inhibit T cell responses (Costa et al., 2018, Prasad et al., 2004, Suh et al., 2003), was expressed most prominently on CAFs and TSKs.”
From Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma (2020) · cites this paper as Suh et al., 2003
In the citing paper
“B7H3 has been shown to promote tumor metastasis and invasion via suppression of both CD8+ and CD4 + T cell proliferation and activity86,87.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [87]
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 1×
“The idea that PD-1 has an immune inhibitory function is supported by the phenotype of PD-1-deficient mice, which develop lupus-like diseases or autoimmune dilated cardiomyopath”
BackgroundCD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · cited 1×
“gif" NDATA ITEM> ]> An optimal T cell response is achieved by a combination of signals delivered through the antigen-specific T cell receptor (TCR) and accessory signals that are either stimulatory or inhibitor”
BackgroundDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Cited by
Items 101–200 of 573
Ingebrigtsen, V. A., Boye, K., Tekle, C., Nesland, J. M., Flatmark, K., & Fodstad, Ø. (2012) · International Journal of Cancer · doi:10.1002/ijc.27566 · Cited by 123
“Its expression can be induced on T-cells, natural killer cells and antigen presenting cells.(11,12) Roth et al.”
BackgroundResultImpact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Furness, A. J. S., Vargas, F. A., Peggs, K. S., & Quezada, S. A. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.05.002 · Cited by 125
Wang, S., & Chen, L. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.03.007 · Cited by 133
Liu, S., Liang, J., Liu, Z., Zhang, C., Wang, Y., Watson, A. H., Zhou, C., Zhang, F., Wu, K., Zhang, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.654684 · Cited by 144
“The difference between CD276 mRNA and protein expression suggests that post-transcriptional regulation mechanisms may cause the discrepancy between transcription and translation (29, 30).”
BackgroundAhmed, M., Cheng, M., Zhao, Q., Goldgur, Y., Cheal, S. M., Guo, H.-F., Larson, S. M., & Cheung, N.-K. V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679852 · Cited by 117
“mice (18), and 4Ig-B7-H3 inhibited NK-mediated lysis of neuroblastoma cells by interacting with a putative inhibitory receptor on the surface of NK cells (19).”
BackgroundThe Future of Immune Checkpoint Cancer Therapy After PD-1 and CTLA-4
Hahn, A. W., Gill, D. M., Pal, S. K., & Agarwal, N. (2017) · Immunotherapy · doi:10.2217/imt-2017-0024 · Cited by 117
B7‐H3 and Its Role in Antitumor Immunity
Loos, M., Hedderich, D. M., Friess, H., & Kleeff, J. H. (2010) · Journal of Immunology Research · doi:10.1155/2010/683875 · Cited by 123
“In mice, B7-H3 protein inhibited T-cell activation and effector cytokine production [38].”
BackgroundInfluentialLuo, L., Zhu, G., Xu, H., Yao, S., Zhou, G., Zhu, Y., Tamada, K., Huang, L., Flies, A. D., Broadwater, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0130126 · Cited by 116
“The strains of C57BL/6 genetic background mice were established by backcrossing chimeric mice with C57BL/6 mice for>10 generations.”
BackgroundInfluentialPD-1/PD-L pathway and autoimmunity
Okazaki, T., & Wang, J. (2005) · Autoimmunity · doi:10.1080/08916930500124072 · Cited by 135
Dondero, A., Pastorino, F., Chiesa, M. D., Corrias, M. V., Morandi, F., Pistoia, V., Olive, D., Bellora, F., Locatelli, F., Castellano, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1064578 · Cited by 119
“inhibitory receptor, is capable of limiting both NK and T cellmediated cytolytic activity.(11,14) B7-H3 is considered an unfavorable prognostic factor in both hematological malignancies(15) and solid tumors, including NB,(16-22) and clinical trials with a fully human antibody(23) are ongoing.”
BackgroundClinical Insights Into Novel Immune Checkpoint Inhibitors
Lee, J. B., Ha, S.-J., & Kim, H. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.681320 · Cited by 112
“Recently, the co-inhibitory function of B7-H3 in CD4 and CD8 T cells was discovered (Suh et al., 2003; Prasad et al., 2004).”
BackgroundHistone lactylation-driven B7-H3 expression promotes tumor immune evasion
Ma, Z., Yang, J., Jia, W., Li, L., Li, Y., Hu, J., Luo, W., Li, R., Ye, D., & Lan, P. (2025) · Theranostics · doi:10.7150/thno.105947 · Cited by 127
The B7 family of immunoregulatory receptors: A comparative and evolutionary perspective
Hansen, J. D., Pasquier, L. D., Lefranc, M., Lopez, V., Benmansour, A., & Boudinot, P. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.10.007 · Cited by 113
“B7-H3 transcripts are up-regulated upon in vitro FN stimulation (in Th1 responses), but are down-regulated durng Th2 responses (Suh et al., 2003).”
BackgroundNikolic, T., & Roep, B. O. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00113 · Cited by 112
The nature of activatory and tolerogenic dendritic cell-derived signal II
Bakdash, G., Sittig, S. P., van Dijk, T., Figdor, C. G., & de Vries, I. J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00053 · Cited by 134
“Similar to CTLA-4, triggering PD-1 limits glucose metabolism and Akt activation, albeit through different mechanisms (Chemnitz et al., 2004).”
InfluentialChen, C., Shen, Y., Qu, Q., Chen, X., Zhang, X., & Huang, J. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.09.006 · Cited by 108
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Guo, C. W., Figueiredo, I., Gürel, B., Neeb, A., Seed, G., Crespo, M., Carreira, S., Rekowski, J., Buroni, L., Welti, J. C., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.09.004 · Cited by 120
B7-H3 overexpression in pancreatic cancer promotes tumor progression
ZHAO, X., Li, D., Zhu, X., Gan, W.-J., Li, Z., XIONG, F., Zhang, Z., Zhang, G., Zhang, X., & Zhao, H. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1212 · Cited by 104
“Previous studies found that B7-H3 deficient mice show airway inflammation (16), experimental autoimmune encephalitis (17) and allergic conjunctivitis in an accelerated pattern (18).”
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies
Park, J. A., & Cheung, N.-K. V. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.006 · Cited by 103
Mahnke, K., Bedke, T., & Enk, A. (2007) · Cellular Immunology · doi:10.1016/j.cellimm.2008.01.004 · Cited by 119
Sun, T., Gao, Q., Qiu, S., Zhou, J., Wang, X., Yi, Y., Shi, J.-Y., Xu, Y., Shi, Y., Song, K., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1278-5 · Cited by 113
B7‐H3 promotes acute and chronic allograft rejection
Wang, L., Fraser, C. C., Kikly, K., Wells, A. D., Han, R., Coyle, A. J., Chen, L., & Hancock, W. W. (2005) · European Journal of Immunology · doi:10.1002/eji.200425518 · Cited by 102
Immunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis
Brunner, A. H., Hinterholzer, S., RISS, P. A., Heinze, G., & Brustmann, H. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.012 · Cited by 101
Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy
Khan, M. S. I., Arooj, S., & Wang, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.651634 · Cited by 106
Stanciu, L. A., Bellettato, C. M., Laza‐Stanca, V., Coyle, A. J., Papi, A. A., & Johnston, S. L. (2006) · The Journal of Infectious Diseases · doi:10.1086/499275 · Cited by 117
“B7-H3 may be an inhibitory molecule for Th1 responses [24].”
BackgroundLi, Y., Huang, J., Foley, N. M., Xu, Y., Li, Y. P., Pan, J., Redmond, H. P., Wang, J. H., & Wang, J. (2016) · Scientific Reports · doi:10.1038/srep31284 · Cited by 106
Schneider, T., Hoffmann, H., Dienemann, H., Schnabel, P. A., Enk, A., Ring, S., & Mahnke, K. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31821c421d · Cited by 105
Targeting Costimulatory Molecules to Improve Antitumor Immunity
Capece, D., Verzella, D., Fischietti, M., Zazzeroni, F., & Alesse, E. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/926321 · Cited by 98
“LIGHT can also engage the lymphotoxin-β-receptor (LTβR) on DCs and provide a crucial signaling resulting in DCs expansion, activation and IL-2 production [102].”
BackgroundResultInfluentialBolandi, N., Derakhshani, A., Hemmat, N., Baghbanzadeh, A., Asadzadeh, Z., Nour, M. A., Brunetti, O., Bernardini, R., Silvestris, N., & Baradaran, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910719 · Cited by 104
“Nakayama et al. revealed that expression of PD-L2 is detected in 28.4 percent of tumor cells related to patients with GC. PD-L2 expression is increased through IFN-γ in these patients.”
BackgroundResultInfluentialCostimulation, Coinhibition and Cancer
Inman, B. A., Frigola, X., Dong, H., & Kwon, E. D. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907780006878 · Cited by 112
“Studies evaluating the precise physiologic role of B7-H3 are conflicting: some groups found evidence suggesting that B7-H3 has positive costimulatory properties [70], other groups have found the exact opposite [71,72].”
BackgroundThe Dendritic Cell-Regulatory T Lymphocyte Crosstalk Contributes to Tumor-Induced Tolerance
Janikashvili, N., Bonnotte, B., Katsanis, E., & Larmonier, N. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/430394 · Cited by 103
“B7-H3 and B7-H4 are members of the B7 family, but, in contrast to their activating counterparts, they trigger inhibitory signals in T lymphocytes and thus contribute to the immunosuppressive function of DCs and thereby to cancer-induced tolerance [44, 212, 225].”
BackgroundLam, K. H. B., Leon, A. J., Hui, W., Lee, S. C.-E. S., Batruch, I., Faust, K., Klekner, Á., Hutóczki, G., Koritzinsky, M., Richer, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27667-w · Cited by 105
“These results are supported by the observed unequal distribution of T in fi ltrating lymphocytes in some GBM and the role of CD276 in suppressing T helper cell immune response in other models 35,36 .”
ResultB7-H3 Augments the Inflammatory Response and Is Associated with Human Sepsis
Zhang, G., Wang, J., Kelly, J., Gu, G., Hou, J., Zhou, Y., Redmond, H. P., Wang, J. H., & Zhang, X. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0904020 · Cited by 95
“In contrast, other groups have reported a negative regulatory function for both human and mouse B7-H3 in T cellmediated immune responses, including an inhibitory effect of B7-H3 on anti-CD3 mAb-induced both T cell proliferation and cytokine production (11, 12, 17).”
BackgroundThe complex role of B7 molecules in tumor immunology
Seliger, B., Marincola, F. M., Ferrone, S., & Abken, H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.010 · Cited by 91
“Although B7-H3 stimulates T-cell proliferation, cytokine secretion and cytolytic activity [30], other studies have demonstrated inhibitory functions of B7-H3, including the impairment of T helper 1 (Th1) responses and NK-cell-mediated lysis [30].”
BackgroundThe CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy
Leung, J., & Suh, W. (2014) · Immune Network · doi:10.4110/in.2014.14.6.265 · Cited by 102
Self-citationBeyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Ziogas, D. C., Theocharopoulos, C., Lialios, P., Foteinou, D., Koumprentziotis, I., Xynos, G., & Gogas, H. J. (2023) · Cancers · doi:10.3390/cancers15102718 · Cited by 98
“Further studies support the inhibitory effect of B7-H3 on T-cells [237,238].”
The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization
Suh, W.-K., Wang, S. X., Jheon, A. H., Moreno, L., Yoshinaga, S. K., Ganss, B., Sodek, J., Grynpas, M. D., & Mak, T. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405259101 · Cited by 93
Self-citationLarge-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma
Zhang, C., Zhang, Z., Li, F., Shen, Z., Qiao, Y., Li, L., Liu, S., Song, M., Zhao, X., Ren, F., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1461304 · Cited by 104
Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells
Zhang, Y., He, L., Sadagopan, A., Ma, T., Dotti, G., Wang, Y., Zheng, H., Gao, X. Y., Wang, D., DeLeo, A. B., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0446 · Cited by 93
“Recent studies have found strong evidence that B7-H3 regulates T-cell–mediated immune response and inhibition of B7-H3 results in T-cell proliferation (26, 27).”
Diagnosis value of serum B7-H3 expression in non-small cell lung cancer
Zhang, G., Xu, Y., Lü, X., Huang, H., Zhou, Y., Lu, B., & Zhang, X. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.01.017 · Cited by 91
B7-H3 Over Expression in Prostate Cancer Promotes Tumor Cell Progression
Yuan, H., Wei, X., Zhang, G., Li, C., Zhang, X., & Hou, J. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.04.103 · Cited by 96
Mao, Y., Chen, L., Wang, F., Zhu, D., Ge, X., Hua, D., & Sun, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6935 · Cited by 97
“B7-H3 expression is found on activated T, natural killer and antigen-presenting cells (6,7), but hardly found in normal organ tissues.”
BackgroundMolecular mechanisms of T‐cell tolerance
Nurieva, R. I., Liu, X., & Dong, C. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01012.x · Cited by 89
“Thus, B7-H3 might provide a negative feedback mechanism for Th1-mediated responses (49).”
BackgroundFrom cancer immunosurveillance to cancer immunotherapy
Stagg, J., Johnstone, R. W., & Smyth, M. J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00566.x · Cited by 105
Petroff, M. G., Kharatyan, E., Torry, D. S., & Holets, L. M. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62990-2 · Cited by 90
Maeda, N., Yoshimura, K., Yamamoto, S., Kuramasu, A., Inoue, M., Suzuki, N., Watanabe, Y., Maeda, Y., Kamei, R., Tsunedomi, R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3564-2 · Cited by 84
“B7-H3 has been reported as a negative regulator that preferentially downregulates T helper type 1-mediated immune responses.(13) On the other hand, another report suggests an opposite function, with human B7-H3 augmenting TCR-mediated T-cell proliferation, interferon-c”
BackgroundExpression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases
Chavin, G., Sheinin, Y. M., Crispen, P. L., Boorjian, S. A., Roth, T. J., Rangel, L. J., Blute, M. L., Sebo, T. J., Tindall, D., Kwon, E. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2262 · Cited by 84
B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells
Lu, H., Shi, T., Wang, M., Li, X., Gu, Y., Zhang, X., Zhang, G., & Chen, W. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1748991 · Cited by 82
“In contrast, bronchoalveolar lavage fluid from B7-H3-deficient mice contained higher IFN-γ concentrations than that from control mice.(45) In addition, soluble B7-H3 could block IL-2 and IFN-γ secretion from allogeneic T cells and further inhibit the allostimulatory capability of DCs.”
BackgroundLi, H., Yang, Z., & Guo, Q. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00789-w · Cited by 94
“However, later studies showed that B7-H3, as a member of the B7 family, acts more as a negative regulator to inhibit the immune response of T cells [94, 95].”
BackgroundMYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 99
“213,327 Also, activated MYC suppresses T and NK cell-mediated immune surveillance by inducing CD276, 328,329 secreting TGF-β that decreases T cell response 330,331 and by transcriptionally repressing STAT1 and STAT2, along with the type I interferon pathway.”
BackgroundThe expression, function, and clinical relevance of B7 family members in cancer
Seliger, B., & Quandt, D. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1293-6 · Cited by 85
B7-H3 Immune Checkpoint Protein in Human Cancer
Karlsen, K. F., Fodstad, Ø., & Nunes‐Xavier, C. E. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190517115515 · Cited by 84
Shi, W. M., Wang, Y., Zhao, Y., Kim, J. J., Li, H., Meng, C., Chen, F., Zhang, J., Mak, D. H. F., Van, V., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf6724 · Cited by 94
A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer
Fauci, J. M., Straughn, J. M., Ferrone, S., & Buchsbaum, D. J. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.08.017 · Cited by 83
Veenstra, R. G., Flynn, R., Kreymborg, K., McDonald-Hyman, C., Saha, A., Taylor, P. A., Osborn, M. J., Panoskaltsis-Mortari, A., Schmitt-Graeff, A., Lieberknecht, E., et al. (2015) · Blood · doi:10.1182/blood-2014-09-603357 · Cited by 78
“to increased IFN-g secretion as well as increased proliferation.(2,11,12) Increased T effector proliferation and inflammatory cytokine secretion could mean increased gut epithelial damage, as is supported by our finding of increased serum concentration of orally administered FITC-dextran.”
BackgroundResultInfluentialSelf-citationGeneration and Characterization of B7-H4/B7S1/B7x-Deficient Mice
Suh, W.-K., Wang, S., Duncan, G. S., Miyazaki, Y., Cates, E., Walker, T., Gajewska, B. U., Deenick, E., Dawicki, W., Okada, H., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00755-06 · Cited by 77
“However, the lack of B7-H4 did not affect hypersensitive inflammatory responses in the airway or skin that are induced by either Th1 or Th2 cells.”
BackgroundMethodInfluentialSelf-citationTumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses
de Souza, A. P. D., & Bonorino, C. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.88 · Cited by 82
Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status
Bhatt, P., Vhora, I., Patil, S., Amrutiya, J., Bhattacharya, C. S., Misra, A. R., & Mashru, R. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.008 · Cited by 87
“Another potential therapeutic agent is B7-H3-specific mAb which is a member of the B7-superfamily of ligands, and is believed to play a role in down-regulation of T-cells involved in tumor immunity [129].”
BackgroundXiong, G., Chen, Z., Liu, Q., Peng, F., Zhang, C., Cheng, M., Ling, R., Chen, S., Liang, Y., Chen, D., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008662 · Cited by 74
T lymphocyte co-signaling pathways of the B7-CD28 family.
Wang, S., & Chen, L. (2004) · PubMed · Cited by 74
The immunoregulatory effects of Qa‐1
Lu, L., Werneck, M. B. F., & Cantor, H. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00418.x · Cited by 72
Co-signal Molecules in T-Cell Activation: Historical Overview and Perspective
Azuma, M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_1 · Cited by 84
Regulation of costimulation in the era of butyrophilins
Arnett, H. A., Escobar, S. M., & Viney, J. L. (2009) · Cytokine · doi:10.1016/j.cyto.2009.03.009 · Cited by 77
CD28 and ICOS: Similar or separate costimulators of T cells?
van Berkel, M. E. A. T., & Oosterwegel, M. A. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.02.007 · Cited by 84
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 78
“Indeed, it appears to downregulate T-cell proliferation and cytokine production [131], Th1 and Th2-mediated immune reactions [132] and inhibit NK cells activity [133].”
BackgroundJin, Y., Zhang, P., Li, J., Zhao, J., Liu, C., Yang, F., Yang, D., Gao, A., Lin, W., Ma, X., et al. (2015) · PubMed · Cited by 70
Tuyaerts, S., Meirvenne, S. V., Bonehill, A., Heirman, C., Corthals, J., Waldmann, H., Breckpot, K., Thielemans, K., & Aerts, J. L. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0906568 · Cited by 73
“In turn, these stimuli can be imprinted upon the T cells, ultimately resulting in an adequately controlled immune response [3–9].”
BackgroundZhan, S., Liu, Z., Zhang, M., Guo, T., Quan, Q., Huang, L., Guo, L., Cao, L., & Zhang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01466 · Cited by 78
REVIEW ARTICLE: B7 Family Molecules as Regulators of the Maternal Immune System in Pregnancy
Petroff, M. G., & Perchellet, A. (2010) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00841.x · Cited by 75
Yim, J., Koh, J., Kim, S., Song, S. G., Ahn, H. K., Kim, Y. A., Jeon, Y. K., & Chung, D. H. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.033 · Cited by 67
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 79
Tran, C. N., Thacker, S. G., Louie, D. M., Oliver, J. A., White, P. T., Endres, J., Urquhart, A. G., Chung, K. C., & Fox, D. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.2989 · Cited by 72
“shown that B7-H3 can mediate inhibitory effects (17, 19, 20) on T cell”
BackgroundRing, S., Maas, M., Nettelbeck, D. M., Enk, A., & Mahnke, K. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202592 · Cited by 76
“ecules have been shown to downregulate proliferation of T cells and cytokine expression thereof (36–39), and in particular for EAE it has been shown that expression of B7H1 ameliorates the course of the disease (38).”
BackgroundPeuker, K., Strigli, A., Tauriello, D. V. F., Hendricks, A., Schönfels, W. V., Burmeister, G., Brosch, M., Herrmann, A., Krüger, S., Nitsche, J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.03.008 · Cited by 72
Swanson, R., Gavin, M. A., Escobar, S. M., Rottman, J. B., Lipsky, B. P., Dube, S., Li, L., Bigler, J., Wolfson, M. F., Arnett, H. A., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201760 · Cited by 64
The effects of MYC on tumor immunity and immunotherapy
Li, J., Dong, T., Wu, Z., Zhu, D., & Gu, H. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01403-3 · Cited by 80
“For example, the deletion of CD276 in T cells can inhibit T cell proliferation and T-helper cell-mediated immune response [60].”
BackgroundB7-H3 expression in ductal and lobular breast cancer and its association with IL-10
Liu, C., Liu, J., Wang, J., Liu, Y., Zhang, F., LIN, W., Gao, A., Sun, M., Wang, Y., & Sun, Y. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1158 · Cited by 66
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation
Yeboah, M., Papagregoriou, C., Jones, D. C., Chan, H. T. C., Hu, G., McPartlan, J. S., Schiött, T., Mattson, U., Mockridge, C. I., Tornberg, U.-C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.141593 · Cited by 59
“Similarly, the reported upregulation of immunoinhibitory receptors, such as CD276 (B7-H3), upon LILRB3 ligation on myeloid cells may restrain the activation of T cells and their proliferative capacity (56, 57).”
BackgroundThe Role of Coinhibitory Signaling Pathways in Transplantation and Tolerance
McGrath, M. M., & Najafian, N. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00047 · Cited by 67
“There appears to be a link between the strength of antigenic stimulation and degree of T cell exhaustion, where larger amounts of epitopes lead to more severe degrees of exhaustion, even with similar viral loads.”
BackgroundResultInfluentialTargeting B7‐1 in immunotherapy
Chen, R., Ganesan, A., Okoye, I., Arutyunova, E. I., Elahi, S., Lemieux, M. J., & Barakat, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21632 · Cited by 67
The immunoregulatory mechanisms of carcinoma for its survival and development
Du, C., & Wang, Y. Z. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-12 · Cited by 69
Chen, W., Liu, P., Wang, Y., Nie, W., Li, Z., Xu, W., Li, F., Zhou, Z., Zhao, M., & Liu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076965 · Cited by 64
Ma, L., Luo, L., Qiao, H., Dong, X., Pan, S., Jiang, H., Krissansen, G. W., & Sun, X. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.07.031 · Cited by 63
“B7H3 is a controversial anti-cancer agent, as two previous reports indicated that B7-H3 negatively regulates T cell responses in mice by inhibiting T cell proliferation, IL-2 production, and Th1-mediated responses which are essential to generate effective anti-tumor immunity [33,34].”
BackgroundThe role of ICOS and other costimulatory molecules in allergy and asthma
Coyle, A. J., & Gutierrez-Ramos, J.-C. (2004) · Springer Seminars in Immunopathology · doi:10.1007/s00281-003-0154-y · Cited by 62
“However, recent data suggest that this molecule functions as a negative regulator of immune responses since T cells from mice deficient in B7H-3 exhibit increased proliferative responses in vitro [ 49 ].”
BackgroundThe role of B7-H3 in tumors and its potential in clinical application
Feng, R.-R., Chen, Y., Liu, Y., Zhou, Q., & Zhang, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108153 · Cited by 62
Baral, A., YE, H. X., JIANG, P. C., Yao, Y., & Mao, Y. Q. (2014) · Oncology Letters · doi:10.3892/ol.2014.2268 · Cited by 61
Pancreatic Ductal Adenocarcinoma: A Review of Immunologic Aspects
Wachsmann, M., Pop, L. M., & Vitetta, E. S. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31824a4d79 · Cited by 72
Suárez, G. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i35.5593 · Cited by 59
Teleost B7 Expressed on Monocytes Regulates T Cell Responses,
Sugamata, R., Suetake, H., Kikuchi, K., & Suzuki, Y. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803371 · Cited by 63
“Suh and colleagues proposed that B7-H3 response depend upon two putative receptors with opposing functions such as CD28 and CTLA-4 in mammals (33).”
BackgroundKleijwegt, F. S., Laban, S., Duinkerken, G., Joosten, A. M., Koeleman, B. P. C., Nikolić, T., & Roep, B. O. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101638 · Cited by 59
“Both molecules are involved in immune regulation: B7-H3 preferentially dampens Th1-mediated responses (29), whereas ICOSL promotes IL-10 secretion by”
Background203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer
Li, M., Sagastume, E. A., Lee, D., McAlister, D. R., DeGraffenreid, A. J., Olewine, K. R., Graves, S. A., Copping, R., Mirzadeh, S., Zimmerman, B. E., et al. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200727190423 · Cited by 64
Yadav, D., Kwak, M., Chauhan, P., Puranik, N., Lee, P. C.-W., & Jin, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.016 · Cited by 63
B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy
Ma, J., Ma, P., Zhao, C., Xue, X., Han, H., Liu, C., Tao, H., Xiu, W., Cai, J., & Zhang, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8784 · Cited by 62
“B7-H3-deficient mice developed experimental autoimmune encephalomyelitis several days earlier than their wild-type littermates [18].”
BackgroundMao, L., Fan, T., Wu, L., Yu, G., Deng, W., Chen, L., Bu, L., Ma, S., Liu, B., Bian, Y., et al. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13143 · Cited by 58
B7-H3 immunoregulatory roles in cancer
Mortezaee, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114890 · Cited by 62
Emerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1
Assal, A., Kaner, J. D., Pendurti, G., & Zang, X. (2015) · Immunotherapy · doi:10.2217/imt.15.78 · Cited by 59
B7-H3 in tumors: friend or foe for tumor immunity?
Li, G. L., Quan, Y., Che, F., & Wang, L. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3508-1 · Cited by 58
“In B7-H3-deficient mice, EAE clinical scores were observed earlier than in wild type mice, and the differentiation of T-helper cells toward Th1 and Th1-mediated immune responses was negatively regulated [22].”
BackgroundInfluentialGupta, M., Chandan, K., & Sarwat, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.009 · Cited by 60
Nurieva, R., Wang, J., & Sahoo, A. (2013) · Immunotherapy · doi:10.2217/imt.13.33 · Cited by 68
ILT4 functions as a potential checkpoint molecule for tumor immunotherapy
Gao, A., Sun, Y., & Peng, G. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.001 · Cited by 61
Metadata
- Authors
- Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., Wakeham, A., Itie, A., Chung, S., Da Costa, J., Arya, S., Horan, T., Campbell, P., Gaida, K., Ohashi, P. S., Watts, T. H., Yoshinaga, S. K., Bray, M. R., Jordana, M., & Mak, T. W.
- Affiliations
- University of Toronto (CA)
- McMaster University (CA)
- Amgen (United States) (US)
- Corresponding author
- Suh, Woong-Kyung
- Mak, Tak W
- ORCID
- Venue
- Nature Immunology
- Published
- 2003-08-17
- Volume
- 4
- Issue
- 9
- Pages
- 899-906
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W2052644931
- Cited by
- 576
- References
- 47
- Citations by year
- 2026: 17 · 2025: 39 · 2024: 32 · 2023: 30 · 2022: 37 · 2021: 48 · 2020: 35 · 2019: 29 · 2018: 12 · 2017: 21 · 2016: 20 · 2015: 25 · 2014: 9 · 2013: 18 · 2012: 29
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- B7-H3, B7 family, T cell proliferation, airway inflammation, interferon-gamma, IL-4, dendritic cells, experimental autoimmune encephalomyelitis, negative regulation of immune response, gene targeting
- MeSH terms
- Animals, Autoantibodies, Dendritic Cells, Encephalomyelitis, Autoimmune, Experimental, Flow Cytometry, Interferon-gamma, Lymphocyte Activation, Lymphocytic choriomeningitis virus, Mice, Inbred C57BL, Orthomyxoviridae, Receptors, Antigen, T-Cell, Vesicular stomatitis Indiana virus, Down-Regulation, Interleukin-4, B7-1 Antigen, Mice, Knockout, Th1 Cells, Mice, B7 Antigens
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.